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A B S T R A C T
Background
Oral cancer is an important global healthcare problem, its incidence is increasing and late-stage presentation is common. Screening
programmes have been introduced for a number of major cancers and have proved effective in their early detection. Given the high
morbidity and mortality rates associated with oral cancer, there is a need to determine the effectiveness of a screening programme
for this disease, either as a targeted, opportunistic or population-based measure. Evidence exists from modelled data that a visual oral
examination of high-risk individuals may be a cost-effective screening strategy and the development and use of adjunctive aids and
biomarkers is becoming increasingly common.
Objectives
To assess the effectiveness of current screening methods in decreasing oral cancer mortality.
Search methods
We searched the following electronic databases: the Cochrane Oral Health Group’s Trials Register (to 22 July 2013), the Cochrane
Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 6), MEDLINE via OVID (1946 to 22 July
2013), EMBASE via OVID (1980 to 22 July 2013) and CANCERLIT via PubMed (1950 to 22 July 2013). There were no restrictions
on language in the search of the electronic databases.
Selection criteria
Randomised controlled trials (RCTs) of screening for oral cancer or potentially malignant disorders using visual examination, toluidine
blue, fluorescence imaging or brush biopsy.
1Screening programmes for the early detection and prevention of oral cancer (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Two review authors screened the results of the searches against inclusion criteria, extracted data and assessed risk of bias independently
and in duplicate. We used mean differences (MDs) and 95% confidence intervals (CIs) for continuous data and risk ratios (RRs) with
95% CIs for dichotomous data. Meta-analyses would have been undertaken using a random-effects model if the number of studies had
exceeded a minimum of three. Study authors were contacted where possible and where deemed necessary for missing information.
Main results
A total of 3239 citations were identified through the searches. Only one RCT, with 15-year follow-up met the inclusion criteria (n = 13
clusters: 191,873 participants). There was no statistically significant difference in the oral cancer mortality rates for the screened group
(15.4/100,000 person-years) and the control group (17.1/100,000 person-years), with a RR of 0.88 (95% CI 0.69 to 1.12). A 24%
reduction in mortality was reported between the screening group (30/100,000 person-years) and the control group (39.0/100,000)
for high-risk individuals who used tobacco or alcohol or both, which was statistically significant (RR 0.76; 95% CI 0.60 to 0.97).
No statistically significant differences were found for incidence rates. A statistically significant reduction in the number of individuals
diagnosed with stage III or worse oral cancer was found for those in the screening group (RR 0.81; 95% CI 0.70 to 0.93). No harms
were reported. The study was assessed as at high risk of bias.
Authors’ conclusions
There is evidence that a visual examination as part of a population-based screening programme reduces the mortality rate of oral cancer
in high-risk individuals. In addition, there is a stage shift and improvement in survival rates across the population as a whole. However,
the evidence is limited to one study, which has a high risk of bias and did not account for the effect of cluster randomisation in the
analysis. There was no evidence to support the use of adjunctive technologies like toluidine blue, brush biopsy or fluorescence imaging
as a screening tool to reduce oral cancer mortality. Further RCTs are recommended to assess the efficacy and cost-effectiveness of a
visual examination as part of a population-based screening programme in low, middle and high-income countries.
P L A I N L A N G U A G E S U M M A R Y
Screening programmes for the early detection and prevention of oral cancer
Review question
This review, carried out by authors of the Cochrane Oral Health Group, was conducted to investigate the effectiveness of current
screening programmes in detecting oral cancer at an early stage and whether or not they can assist in decreasing deaths due to oral
cancer.
Background
Oral cancer is increasing worldwide and it is the sixth most common cancer overall. The highest rates of oral cancer occur in the most
disadvantaged sections of the population. Important risk factors in the development of the disease are tobacco, alcohol, age, gender
and sunlight although a role for candida (which causes thrush) and the human papillomavirus (which causes warts) has also been
documented. People who are heavy drinkers and also smoke have 38 times the risk of developing oral cancer compared with people
who do neither. These factors are considered to be especially important in the development of the disease in young people, a group
experiencing an increasing incidence of the disease, particularly in countries with a high incidence of it.
Geographic variation in the occurrence of oral cancer around the world is wide. For example it is the most common cancer for men
in India, Sri Lanka and Pakistan and 30% of all new cases of cancer in these countries is oral cancer whereas only 3% of new cases of
cancer in the United Kingdom are oral cancer.
When people first seek medical help, their oral cancer is usually at a late or advanced stage and the effects of the condition as well
as the treatment for it can be extremely debilitating. Death rates from oral cancer and the negative effects of the disease are high and
increasing rather than declining as for other cancers such as breast and colon.
Prevention screening programmes for other cancers have proven to be effective in early detection. However, whilst there maybe
advantages to screening there are disadvantages because screening has the potential to produce either false positive or false negative
results. Screening can be targeted at high-risk groups, it can be opportunistic, for example when people attend health services for other
reasons, or can be done by looking at statistics across the population as a whole.
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The aim of preventive screening for early detection of oral cancer is to screen individuals for pre-cancerous conditions which are lesions
such as leukoplakia. The most common screening method is visual inspection by a clinician but other techniques include the use of a
special blue dye, the use of imaging techniques and measuring biochemical changes to normal calls.
Study characteristics
The evidence on which this review is based is up to date as of 22 July 2013. The only study included was based in rural areas of the
city of Trivandrum in Kerala, India. The study included 191,873 apparently healthy adults aged 35 years or older living in 13 clusters
with an average of 14,759 participants in each cluster. Screening took place in seven clusters (96,517 participants) and six clusters acted
as a control (95,356 participants). Participants were excluded if they were bedridden, if they had open tuberculosis, other debilitating
diseases or were already suffering from oral cancer.
Healthcare workers trained in the detection of oral lesions undertook the screening of participants and the social history of participants
including use of paan, tobacco, alcohol and dietary supplements was recorded.
Key results
The review found that overall there is not enough evidence to decide whether screening by visual inspection reduces the death rate for
oral cancer and there is no evidence for other screening methods. However, there is some evidence that it might help reduce death rates
in patients who use tobacco and alcohol although the only included study may be affected by bias.
Quality of evidence
The evidence presented is of low quality and limited to one study assessed as at high risk of bias.
B A C K G R O U N D
Description of the condition
Oral cancer is the sixth most common cancer globally and rep-
resents a group of conditions with a range of sites and a var-
ied aetiology. Its annual estimated incidence is approximately
275,000, but unlike many other cancers, its incidence is increasing
(Warnakulasuriya 2009). There is a wide geographic variation in
the incidence of the disease with two-thirds of the burden born by
low-income and middle-income countries from South and South-
East Asia, Latin America and Eastern Europe. However, the inci-
dence continues to rise in theWest (IARC 2010) and the age stan-
dardised incidence of oral cancer in Western Europe has steadily
increased over the past two decades (Boyle 2005). Within the
European Union countries, the highest male incidence rates are
found in France and Hungary, whilst the lowest rates are found in
Greece and Cyprus (IARC 2010). India, Sri Lanka and Pakistan
have the highest levels of disease, making it the most common
cancer for men in these countries and accounts for up to 30% of
all new cases of cancer compared to 3% in the United Kingdom
(UK) and 6% in France (Cancer Research UK). The age-adjusted
incidence rate from these countries cancer registries range from3.4
to 13.8 per 100,000 (Ministry of Health 2005; Warnakulasuriya
2009). The incidence of oral cancer for men in Brazil is second
only to France and India with an estimated crude rate of 11 per
100,000. In the UK, the incidence of oral cancer is increasing
(Conway 2006; Doobaree 2009) and 6236 cases of oral cancer
were diagnosed in 2009 (Cancer Research UK). This represents a
doubling of the number of cases seen in 1989 and represents a year
on year increase of approximately 2.7% per year (Warnakulasuriya
2009). The incidence of oral cancer is strongly associated with
social and economic deprivation (Scully 2009; Conway 2010a),
with the highest rates occurring in themost disadvantaged sections
of the population. Across Europe, inequalities tend to be observed
among men, particularly in the UK and Eastern Europe (Conway
2010b).
Important risk factors in the development of the disease are to-
bacco, betel quid, alcohol, age, gender and sunlight. More re-
cently, a role for candida and the human papillomavirus (HPV)
has been documented (Scully 2009). Epidemiological evidence
from US populations indicates a strong association between HPV
and oropharyngeal cancers (Cleveland 2011). Incidence of HPV
globally is unknown but thought to be rising, but estimates from
the United States of America (USA) show a substantial increase of
HPV-positive oropharyngeal cancers, rising by 225% in the pe-
riod between 1984 and 2004 (Sanders 2011). Increased consump-
tion of alcohol has been implicated in the increasing incidence
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of the disease in the UK (Hindle 2000) at a time when tobacco
use is falling (Ogden 2005), although the precise mechanism re-
mains unclear (Ogden 1998). Heavy drinkers and smokers have
38 times the risk of developing oral cancer compared to abstainers
(Blot 1988). This is thought to be due to acetaldehyde, the first
metabolite of alcohol, which is classified as a Group 1 carcinogen
and is also present in tobacco (Salaspuro 2011). Historically, the
risk of developing oral cancer increased with age, however, the age
group with the highest incidence (26.8%) in the USA between
2003 and 2007 was between 55 and 64 years of age (SEER 2010).
In contrast, many patients from high-incidence countries are be-
low the age of 40 years of age (Warnakulasuriya 2009).
Of equal concern to the increasing incidence, is the lack of any
change in the age-standardised mortality rates, despite advances
in surgical and management techniques. This is unlike the falling
rates for cancer of the breast and colon (Cancer Research UK).
The five-year survival rates for oral cancer for most countries is
approximately 50% (Warnakulasuriya 2009). These have been es-
timated at 3 to 4 per 100,000 men and 1.5 to 2.0 per 100,000
for women respectively (Warnakulasuriya 2009). Mortality rates
from oral cancer have also increased in certain European coun-
tries (La Vecchia 2004). The most important determinant factor
in cancer survival is diagnostic delay (Onizawa 2003; McLeod
2005), as over 60%of patients present with stage III and IV disease
(Lingen 2008), meaning that their management is complex and
multidisciplinary. The stage at diagnosis significantly affects five-
year survival, with survival rates approaching 80% for stage I dis-
ease, whilst dropping significantly for stage IV disease (Rusthoven
2010). In addition, the morbidity associated with surgery is high,
the rate of second primary tumours is greater than any other type
of cancer (3% to 7% per annum) (Day 1992) and is more often
the cause of death (Lippman 1989).
Description of the intervention
Prevention strategies are important to meet theWorld Health Or-
ganization’s (WHO) resolution to incorporate oral cancer into na-
tional cancer control programs (Petersen 2009). Although it is im-
portant to continue to clarify the public health message and pro-
mote primary prevention, determining the feasibility of a national
screening programme is an important step in the prevention of
the disease. The National Screening Committee define screening
as “a process of identifying apparently healthy people who may be
at increased risk of a disease or condition” (NSC 2010). Screening
can be undertaken across the whole population, opportunistically,
when individuals are attending for some other purpose, or selec-
tively, where high-risk groups are targeted. Programmes for major
cancers, such as breast, cervical and bowel cancer have effectively
improved the mortality rates and helped to decrease the incidence
of these cancers (Gøtzsche 2006; Hewitson 2007). However, it is
important to consider both the harms and benefits of any screen-
ing programmes. For example, screening for breast cancer has re-
cently been associated with over-diagnosis and unnecessary treat-
ment causing further physical and psychological harms (Gøtzsche
2013) and so any future programme should always balance these
considerations.
How the intervention might work
Screening is predicated on the idea that malignancy is preceded by
clinically evident lesions, which if identified early and removed,
can either prevent their malignant transformation or reduce their
staging. The majority of oral carcinomas are preceded by vis-
ible lesions, known as potentially malignant disorders (PMDs)
(Warnakulasuriya 2007; van der Waal 2009) that exhibit oral ep-
ithelial dysplasia (Scully 2009). A visual screen is not surgically
invasive, is painless and has been found to be socially acceptable.
Additional Table 1 highlights the different types of PMDs that
were considered by the WHO’s Working Party on Oral Cancer
and Precancer to be important (Warnakulasuriya 2007). Themost
common form of PMD is leukoplakia (Napier 2008), which has
an estimated global prevalence of 2.6% (95% confidence interval
(CI) 1.72% to 2.74%) (Petti 2003). However, the extent and rate
of progression of dysplasia in leukoplakia is not uniform and can
vary from site to site and within the same lesion (Napier 2008).
The overall malignant transformation rate for oral leukoplakia is
up to 5% (Scully 2009; van der Waal 2009), but the lack of uni-
formity in the extent and the rate of dysplastic change in PMDs
means that predicting malignant transformation is problematic.
However, there remains a consensus in the literature that the ma-
jority of cancers are preceded by a detectable pre-clinical phase
(Napier 2008).
Although there have been no randomised controlled trials (RCTs)
in any developed or low-prevalence populations (Brocklehurst
2010a), Speight et al demonstrated using a simulated model that
an oral examination of high-risk individualsmay be a cost-effective
screening strategy (Speight 2006). A recent diagnostic test accuracy
review looking at the accuracy of conventional oral examination as
a screening test in primary settings found sensitivity estimates to
range from 0.50 (95% CI 0.07 to 0.93) to 0.99 (95% CI 0.97 to
1.00) with specificity estimates 0.98 (95%CI 0.92 to 1.00) to 0.99
(95% CI 0.99 to 0.99) (Walsh 2013). Positive predictive values
ranged from 0.31 to 0.86; negative predictive values ranged from
0.96 to 0.99 (Walsh 2013). Other adjunctive and diagnostic aids
can be grouped into visual staining (toluidine blue), oral cytology
using brush biopsy and a number of light-based techniques (e.g.
ViziLite (Zila Pharmaceuticals, AZ, USA) and VELscope (LED
Dental Inc, BC, Canada)) (Brocklehurst 2010a).
Why it is important to do this review
The RCT provides the strongest level of evidence on which to
base clinical decisions (Clarkson 2003) and so represents a level
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of rigor that is appropriate for assessing the effectiveness of any
intervention or programme. As with other cancers, screening for
oral cancer and PMDs has potential advantages and disadvantages
(Speight 1992). Screening and treatment may offer the oppor-
tunity to reduce the incidence of invasive lesions and also could
help in decreasing the mortality rates associated with oral cancer.
Speight et al demonstrated that targeting high risk groups could
result in a pronounced increase in the Quality Adjusted Life Years
saved and any associated stage shifts could produce significant cost
savings (Speight 2006). However, screening also has the poten-
tial to generate false positives and false negatives (Wilson 1968).
Earlier versions of this Cochrane review concluded that there was
insufficient evidence to support or refute the use of screening for
oral cancer in the general population (Kujan 2003; Kujan 2006;
Brocklehurst 2010c). The purpose of this latest update was to de-
termine whether the evidence base had changed.
O B J E C T I V E S
To assess the effectiveness of current screeningmethods in decreas-
ing oral cancer mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of screening programmes for
the early detection of oral cancer or potentially malignant disorder
(PMD), which report on the associated mortality rates subsequent
to the screen.
Types of participants
Participants involved in population, selective (high-risk) or oppor-
tunistic screening programmes were included.
Types of interventions
Any health technology used in a screening programme for the
detection of oral cancer or PMD:
• visual screening;
• visual staining using toluidine blue;
• oral cytology using brush biopsies;
• fluorescence imaging and light-based techniques.
As this was not a diagnostic test accuracy review, the definition of
a positive case in each of these categories was not defined; each
study was assessed on an individual study-by-study basis.
Types of outcome measures
The primary outcome measure for this review was oral cancer
mortality.
Other outcomes included were:
• incidence of oral cancer or PMD;
• stage at diagnosis;
• adverse effects (outcomes from false positive or false
negative results, if known);
• cost data (where reported).
Search methods for identification of studies
Electronic searches
For the identification of studies included or considered for this
review, detailed search strategies were developed for each database
searched. These were based on the search strategy developed for
MEDLINE (OVID) but revised appropriately for each database
(Appendix 1). The search strategies for MEDLINE and CAN-
CERLIT used a combination of controlled vocabulary and free
text terms. They were linked with the Cochrane Highly Sensitive
Search Strategies (CHSSS) for identifying RCTs in MEDLINE:
sensitivity maximising versions (2008 revision) as referenced in
Chapter 6.4.11.1 and detailed in boxes 6.4.a and 6.4.c of the
Cochrane Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011) (Higgins 2011). The search of EM-
BASE was linked to the Cochrane Oral Health Group filter for
identifying RCTs.
Databases searched
We searched the following electronic databases.
• The Cochrane Oral Health Group’s Trials Register (to 22
July 2013) (Appendix 2).
• CENTRAL (The Cochrane Library 2013, Issue 6)
(Appendix 3).
• MEDLINE via OVID (1946 to 22 July 2013) (Appendix
1).
• EMBASE via OVID (1980 to 22 July 2013) (Appendix 4).
• CANCERLIT via PubMed (1950 to 22 July 2013)
(Appendix 5).
Searching other resources
The following journals were handsearched for this review to 2010:
• Oral Oncology
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• British Dental Journal
• Cancer
• Cancer Research
• Community Dental Health
• Community Dentistry and Oral Epidemiology.
For this update, only handsearching done as part of the Cochrane
Worldwide Handsearching Programme and uploaded to CEN-
TRALwas included. See the Cochrane Masterlist of handsearched
journals for information on journals and issues searched to date.
Language
There were no non-English papers that required translation. Had
such trials been identified theywould have been translated through
The Cochrane Collaboration.
Unpublished trials
The bibliographies of included papers and relevant review articles
were checked for studies not identified by the search strategies
above. The authors of identified and included studies were also
contacted to identify unpublished or ongoing trials.
Data collection and analysis
Selection of studies
The titles and abstracts obtained from initial electronic searches
were scanned for relevance independently by two of the review
authors (Paul Brocklehurst (PRB), Anne-Marie Glenny (AMG)).
Reports from the studies that fulfilled the inclusion criteria were
obtained. When there was insufficient data in the study title to
determine whether a study fulfilled the inclusion criteria, the full
reportwas obtained and assessed independently by the same review
authors. Disagreement was resolved by discussion.
Data extraction and management
All studies meeting the inclusion criteria underwent data extrac-
tion and an assessment of risk of bias was made. Studies rejected
at this and subsequent stages were recorded in the table of ex-
cluded studies. Data from each included study was extracted inde-
pendently using the tool developed and reported in Kujan 2005.
Differences were again resolved by discussion. If a single publica-
tion reported two or more separate studies, then each study was
extracted separately. If the findings of a single study were spread
across two or more publications, then the publications were ex-
tracted as one. For each study with more than one control or
comparison group for the intervention, the results were extracted
for each intervention arm. For each trial the following data were
recorded.
• Year of publication, country of origin and source of study
funding.
• Details of the participants including demographic
characteristics and criteria for inclusion.
• Details on the type of intervention and comparisons.
• Details on the study design.
• Details on the outcomes reported, including method of
assessment.
Assessment of risk of bias in included studies
Assessment of risk of bias was conducted by three review authors
(PRB, AMG, Lucy O’Malley (LO)) using the Cochrane risk of
bias assessment tool. The domains that were assessed for each
included studywere: sequence generation, allocation concealment,
blinding, completeness of outcome data, risk of selective outcome
reporting and risk of other potential sources of bias.
A description of the domains was tabulated for each included trial,
along with a judgement of the risk of bias in accordance with the
Cochrane Handbook for Systematic Reviews of Interventions 5.1.0
(Higgins 2011). A summary assessment of the risk of bias across all
the domains for each study was then undertaken (Higgins 2011).
• Low risk of bias - a low risk of bias for all key domains.
• Unclear risk of bias - an unclear risk of bias for one or more
key domains.
• High risk of bias - a high risk of bias for one or more key
domains.
Measures of treatment effect
For dichotomous outcomes, the estimate of effect was expressed
as risk ratios with 95% confidence intervals; for continuous out-
comes, mean differences were used with 95% confidence intervals.
Unit of analysis issues
The analysis for cluster randomised trials was undertaken, when
feasible, at the same level of randomisation, or at an individual
level with the effect of clustering being accounted for.
Assessment of heterogeneity
The significance of any discrepancies in the estimates of the treat-
ment effects from the different trials was assessed by means of
Cochran’s test for heterogeneity, considered statistically significant
at the level of P value < 0.1 (Higgins 2011). The percentage total
variation across the included studies was used to quantify hetero-
geneity and expressed as I2, with a value over 50% representing
substantial heterogeneity (Higgins 2011).
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Assessment of reporting biases
Publication bias would have also been assessed using funnel plot
asymmetry (Higgins 2011).
Data synthesis
Meta-analyses would have been undertaken if the number of trials
had exceeded a minimum of three. Risk ratios would have been
combined for dichotomous data, and mean differences for con-
tinuous data using a random-effects model, if data had allowed.
R E S U L T S
Description of studies
A total of 3239 citations were identified through the MED-
LINE searches. The full text of 30 articles were retrieved. Fol-
lowing further screening, 26 of these were excluded with reasons
(Characteristics of excluded studies). One of the excluded stud-
ies did undertake a community-based randomised controlled trial
to examine the efficacy of toluidine blue in Taiwan (Su 2010).
However, the primary aim was to determine whether toluidine
blue enhanced the detection rate for potentially malignant disor-
ders (PMD), not mortality rate. Although they did link the ex-
amined cohort with the National Cancer Registry to determine
five-year follow-up, the power calculation was based on the former
not the latter. As a result, the study was excluded from this review
but included in an accompanying diagnostic test accuracy review
(Walsh 2013). Only one study (four reports) met the inclusion
criteria (Sankaranarayanan 2000). The principal investigator of
the included trial (Dr Sankaranarayanan) was also contacted and
no other relevant trials were identified (Figure 1).
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Figure 1. Study flow diagram.
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The included study (Trivandrum Oral Cancer Screening Study;
Sankaranarayanan 2000) was designed to have an 80% power at
the 5% significance level to detect a 35% reduction in the cumula-
tive mortality rate of oral cancer in 12 years of enrolment between
the intervention and the control groups. The study commenced
in October 1995 and three rounds of screening at three-year inter-
vals were planned for the study. The first round was completed in
May 1998 and the second was completed in June 2002. The third
round was completed in October 2004. A final round of screening
was completed in 2009.
All participants (n = 191,873) were apparently healthy residents
aged 35 years or older and lived in 13 rural clusters around Trivan-
drum City, Kerala, India, The mean number of eligible partici-
pants in each cluster was 14,759. These clusters were allocated
into an intervention arm (n = 7) and a control arm (n = 6) by a
blocked randomisation process. Those residents who were bedrid-
den, suffering from open tuberculosis or other debilitating diseases
were excluded alongside those participants who had already been
diagnosed with oral cancer prior to entry into the study.
In the intervention arm, non-medical university graduates were
initially trained and were provided with two simple manuals on
oral visual examination with colour photographs and descriptions
of various oral lesions. Eligible participants were interviewed and
information relating to demographic, social and personal habits
including the use of paan, tobacco, alcohol and dietary supple-
ments was recorded. Tobacco and alcohol cessation advice was
provided as appropriate. Oral visual inspections were performed
in daylight with the help of a flashlight. All the intra-oral sites were
carefully examined and palpated and the neck was also palpated
to detect enlarged lymph nodes. The findings were recorded as
normal, non-referable lesions and referable lesions.
Participants who had a positive screen were referred for exami-
nation by a dentist or physician for confirmation. It is unclear
whether these clinicians were also trained in the recognition of oral
cancer or PMDs. Oral biopsies were performed in those with clin-
ically confirmed homogeneous leukoplakias, non-homogeneous
leukoplakias, oral submucous fibrosis and oral cancers. Surgical
excision was undertaken for leukoplakia wherever possible. All
PMDs were reviewed regularly.
In the control arm, participants were visited by a “control health
worker” who recorded the same sociodemographic information
and measured height, weight, blood pressure and respiratory peak
flow measurements. The health workers in the control arm were
not trained to undertake a visual oral inspection.
Oral cancer mortality was reported as the main outcome measure.
Of the 96,517 eligible subjects in the intervention arm, 25,144
(26.1%) had one, 22,382 (23.2%) had two, 22,008 (22.8%) had
three and 19,288 (20.0%) had four cycles of screening. 49,179
(51.0%) individuals were screened in the first round and 55,993
(58.0%), 64,898 (67.2%) and 43,014 (44.6%) were screened in
the second, third and fourth cycles respectively. The participation
rate (at least one screen) for this group was 88,822 (92%); males
(86%) and females (94%). Of the 95,356 eligible subjects in the
control group, 43,992 (46.1%) were screened in the fourth cycle.
Demographic details were not provided for the final (fourth) cycle
of screening, but were provided for the first three cycles (Addi-
tional Table 2). Across the period of the study (all four cycles),
6.3% (n = 5586) of subjects screened as part of the intervention
group had a referable lesion and 59% (n = 3298) of these screen
positive subjects complied with referral (Additional Table 3). The
control group consisted of 95,356 persons. 46% (n = 43,992) of
the control group were screened in the final (fourth) cycle and
2.6% (n = 1163) of these were found to have a referable lesion
with 16.3% (n = 189) complying with referral.
Risk of bias in included studies
Allocation
Sequence generation
The randomisation procedure was conducted using restricted
block randomisation. The exact detail of this process was not pro-
vided, although the clusters were grouped into blocks of four and
allocated at random to screening or non-screening groups from
the six possible combinations available to each block of four. Clus-
tering was not accounted for in the analysis.
Allocation concealment
No detail of allocation concealment was provided, although the
principal investigator confirmed that this was not undertaken.
Blinding
Blinding of outcome assessment
No blinding was undertaken in the study, but the review authors
judge that the outcome and its measurement are unlikely to be
influenced by this. As a result, the risk of bias based on the lack of
blinding is considered to be low.
Incomplete outcome data
Withdrawals and drop-outs were not described clearly andmissing
data will have increased the risk of bias. Of those whowere referred
with positive lesions, 59% of individuals in the screening group
complied with referral and 16% in the control group (Additional
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Table 3). The analysis was carried out on an intention-to-treat
(ITT) basis.
Selective reporting
The study protocol was not made available, but it appears that
the published reports include all the expected and pre-specified
outcome measures.
Other potential sources of bias
Positive cases were referred to dentists and physicians to make
a diagnosis, but it is unclear whether standardised criteria were
used by these clinicians or whether they had received any formal
training. It is stated that subjects with confirmed oral cancer and
PMDs were biopsied and those with confirmed oral cancer were
referred. However, this detail was absent and only 26.4% and
26.0% of subjects with a PMD had a biopsy in the second or third
cycle respectively. It is not clear whether all suspected oral cancer
cases did receive a biopsy, but given the definition of “interval
cases” in the third paper, it would appear not.
In addition, it is stated in the third paper that the reference inves-
tigation for final diagnosis was clinical examination by physicians
or histology or both. As it is not possible to diagnose early malig-
nancy by visual appearance alone, this may have led to substantial
under-reporting of oral cancer. The lack of a histological diagnosis
for many of the PMDs also makes it difficult to accurately assess
the correct diagnosis and true prevalence of these disorders. Preva-
lence of PMDs is provided in detail for the first two cycles only.
The fourth paper presents incidence and mortality data for each
round of screening. Neither the third or fourth papers present data
regarding prevalence of PMDs.
In the included study the health workers reported on 24 baseline
variables including multiple age strata, occupation, education, in-
come, household belongings such as television and personal habits
of chewing, smoking, and drinking. The intervention and control
cohorts appear to have been well matched for the stratified vari-
able age at the baseline. However, the distribution of income, ed-
ucation, use of tobacco and alcohol varied across the intervention
and control groups, with the former demonstrating higher levels
of consumption (Additional Table 2). Men smoked and drank
alcohol more than females in both groups, but the prevalence of
chewing tobacco was not as marked across gender differences. Al-
though, such differences in baseline variables might be expected
to occur in cluster randomised studies, the differences between the
numbers who used tobacco and alcohol need to be borne in mind
when interpreting the results.
Effects of interventions
The included study reported data onoral cancer incidence, disease-
specific mortality, and stage at diagnosis after 15-years follow-up.
Data on quality of life and all cause mortality were not reported.
Oral cancer mortality
There was a 12% reduction in oral cancer mortality between the
intervention and control arms, but this difference was not statisti-
cally significant. Over the four cycles (15 years), 138 of 279 sub-
jects with oral cancer in the intervention group and 154 of the
244 cases in the control group died, which represents a mortality
rate of 15.4 and 17.1 per 100,000 person-years respectively (risk
ratio (RR) 0.88; 95% confidence interval (CI) 0.69 to 1.12). Age-
adjusted rates were 18.9 per 100,000 person-years in the inter-
vention group and 19.7 per 100,000 person-years in the control
(Additional Table 4).
There was a 24% reduction in oral cancer mortality between the
intervention and control arms for those participants who used
tobacco or alcohol or both and this difference was statistically
significant. Over the four cycles (15 years), 129 of 254 subjects
with oral cancer in the intervention group and 147 of the 232
cases in the control group died, which represents a mortality rate
of 30.0 and 39.0 per 100,000 person-years respectively (RR 0.76;
95% CI 0.60 to 0.97) (Additional Table 5). Age-adjusted rates
were 29.1 per 100,000 person-years in the intervention group and
37.1 per 100,000 person-years in the control (Additional Table
4).
Although data presented after four cycles (15 years) were not di-
vided by gender, the three-year cycle data (nine years) showed a
significant reduction of 43% in mortality rates for men from 42.9
per 100,000 person-years in the control group to 24.6 per 100,000
person-years in the intervention group. For women, there was a
22% reduction, from 50.7 to 39.4 per 100,000 person-years, but
this did not reach significance.
For the participants that adhered to all four cycles of the screening
programme, there was a 79% reduction in oral cancer mortality
(81% amongst the users of tobacco or alcohol or both) compared
to the control, which was statistically significant (Additional Table
6).
Oral cancer incidence
Among the 96,517 participants screened in the intervention
group, 5586 (6.3%) were found to have referable lesions. Of these,
3298 (59%) compliedwith the referral criteria for confirmatory ex-
amination by dentists or medical officers in special clinics. Healthy
mucosa or benign lesions were found in 770 (23.3%). The num-
ber of PMDs was 2336 (70.8%) (lichen planus (n = 53), homoge-
nous leukoplakia (n = 898) and submucous fibrosis (n = 573))
and growths suspicious of oral cancer 192/3298 (4%). Of those
diagnosed with PMDs, 21.4% (n = 499), underwent biopsies and
4.4% (n = 22) were confirmed squamous cell carcinoma. Of those
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diagnosed with suspicious growths, 84.9% (n = 163) were con-
firmed as squamous cell carcinoma and 1.6% (n = 3) as verrucous
carcinoma.
The detection rate of PMDand oral cancer in the first, second, and
third and fourth rounds of screening were 28.0, 11.9, 11.6 and 3.9
per 1000 screened subjects respectively. The crude incident rate
of oral cancer was 31.2 per 100,000 person-years in the screening
group and 27.2 per 100,000 person-years in the control group,
with a risk ratio of 1.14 (95% CI 0.91 to 1.44). Age-adjusted
incidence rates were 37.1 per 100,000 person-years and 30.8 per
100,000 person-years respectively (Additional Table 4).
Test performance
Across the four cycles (15 years) of the programme, the reported
sensitivity of the visual examination in detecting oral cancer was
67.4% (188/279) (Additional Table 4). No information on the
specificity or the positive predictive value of the programme was
recorded.
Survival
Survival rates were calculated by comparing the proportion of
patients alive at five years after diagnosis across the two groups.
A significantly higher five-year survival rate was reported in the
screened group (55.5%) compared to the control (43.4%) (P value
= 0.003).
Stage shift at diagnosis
There was a statistically significant stage shift in the cancers that
were diagnosed in the screened group, based on the criteria of
the International Union Against Cancer/American Joint Commit-
tee on Cancer (UICC/AJCC). In the screened group, 147/279
(52.6%) cases were in stage III or worse at diagnosis, as opposed
to 159/244 (65.2%) of cases in the control group (RR 0.81; 95%
CI 0.70 to 0.93) (Additional Table 4; Additional Table 7). For
users of tobacco, alcohol or both, 138/254 (54.3%) cases were in
stage III or worse at diagnosis in the screened group, as opposed
to 154/232 (66.4%) of cases in the control group (RR 0.82; 95%
CI 0.71 to 0.95) (Additional Table 5; Additional Table 7).
Cost-effectiveness
The costs associated with the screening programme were reported
after three cycles (nine years) (Subramanian 2009) (Additional
Table 8). The benefit produced by a screen was 269.31 life-years
saved per 100,000 for all the individuals and 1437.64 for those
at high risk. The incremental cost per life-year saved was USD
835 for all individuals, which reduced to USD 156 for high-risk
individuals. This fulfils the target set by the World Health Orga-
nization (WHO) Commission on Macroeconomics and Health
(WHO 2001), who define an intervention to be cost-effective
when its cost-effectiveness ratio is less than a country’s gross do-
mestic product per capita. Subramanian argues that this provides
good evidence that opportunistic screening of high-risk groups is
cost-effective (Subramanian 2009).
D I S C U S S I O N
The incidence of oral cancer is increasing in low, middle and high-
income countries (Warnakulasuriya 2009). Delays in diagnosis
and management persist (Onizawa 2003; McLeod 2005) and are
associated with a dramatic deterioration in five-year survival rates.
Effective primary and secondary prevention strategies are critical
in delivering the World Health Organization’s (WHO) resolution
that oral cancer should be an integral part of national cancer con-
trol programmes (Petersen 2009).
Given that the majority of oral carcinomas are preceded by visible
lesions (Scully 2009), determining the efficacy and effectiveness of
screening warrants attention, whilst balancing the potential ben-
efits with any potential negative consequences of any programme
(Wilson 1968).
Summary of main results
The study reported a sensitivity of the visual examination in de-
tecting oral cancer was 67.4%. However, the data for users of to-
bacco, alcohol or both demonstrated a reduction inmortality rates
of 24% after four cycles (15 years), which was statistically signif-
icant. In addition, there was a statistically significant difference
in the number of stage III cancers between the intervention and
control arms, suggesting that the screening programme was iden-
tifying cancers at an early stage. When these results are combined
with the significant stage shift and survival rate in the intervention
group, it would appear that visual examination could be effective
at reducing mortality rates for oral cancer when used within a tar-
geted screening programme. However, the included study had a
high risk of bias.
Overall completeness and applicability of
evidence
The purpose of health care is to improve both the quantity and
quality of life (Kaplan 2005). The evidence from the Kerala trial
(Sankaranarayanan 2000) is that visual screening can reduce the
mortality rate in users of tobacco, alcohol or both and can produce
a stage shift. Given that late stage disease is recognised as a major
contributory factor for cancer survival (Onizawa 2003; McLeod
2005), it would appear that the screening of high-risk individuals
could be warranted. However, the evidence from this study stems
from a population with a high incidence of oral cavity cancer,
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and its applicability to other countries with lower incidence rates
is unknown. In addition, the efficacy of the early management
of potentially malignant disorders (PMDs) is a controversial area
(Holmstrup 2007;Holmstrup 2009). Holmstrup argues that even
if early lesions are surgically removed, the risk of malignant change
can remain as a result of “field change” i.e. the lesion represents
only a small area of a wider field of damaged mucosa (Holmstrup
2007; Holmstrup 2009).
The trial used non-medical university graduates, trained specif-
ically to perform visual inspection of the oral mucosa, with the
help of a flashlight. The screening was undertaken in individu-
als own home, with the health workers going ’door-to-door’. The
ability to translate this screening model to other settings is unclear.
However, the Kerala study does demonstrate the potential of allied
health professionals to screen for oral cancer and PMDs. This is
becoming increasingly relevant as more regulators allow patients
to directly access allied providers of dental care (oral health prac-
titioners), in addition to the dentist.
The cost-effectiveness of the Kerala study was reported after
three cycles (nine years) (Subramanian 2009), demonstrating that
1437.64 life-years could be saved per 100,000 high-risk individ-
uals, with an incremental cost per life-year saved of USD 156.
According to the authors, this fulfils the target set by the WHO
Commission on Macroeconomics and Health, who define an in-
tervention as being cost-effective when its cost-effectiveness ratio
is less than a country’s gross domestic product per capita. How-
ever, these results also need to be read in context of the relative
prevalence of the condition and account for the potential problem
of compliance; out of the 5586 participants that were screened
positive, only 59% (n = 3298) complied with referral.
The consideration of both the benefits and harms of screening is
an essential component of any programme (Wilson 1968) and is
fundamental to the satisfactory introduction of any technology
into daily practice (Duffy 2001). The sensitivity reported in the
Kerala study was relatively low (67%). In addition, false positives
can have unintended psychological consequences, for example, in-
creasing anxiety and exposing the patient to unnecessary further
investigations. However, these could be reduced by careful patient
management and by educating screened patients about the posi-
tive benefits of screening (Speight 1992). Recent studies by Brock-
lehurst, highlighted the need to train general dental practitioners
to discuss positive findings (Brocklehurst 2010b) and the need
for standardised criteria to avoid both under and over-referral in
clinical practice (Brocklehurst 2010).
Quality of the evidence
TheKerala study had a number ofmethodological weaknesses that
may have introduced bias. These included a lack of detail about
the process of sequence generation to ensure random assignment,
no analysis of the impact of clustering on the results and no detail
about allocation concealment. In addition, there was no blinding
of the outcome assessment and withdrawals and drop-outs were
not described. More importantly, only 59% of individuals with
screen-positive lesions in the intervention arm complied with re-
ferral and it was unclear whether the clinicians who saw these pa-
tients followed any standardised criteria. In addition, only 26.4%,
26.0%, and 21.4% of subjects had a biopsy in the second, third
cycle or fourth cycle respectively, with no detail being provided
from the first cycle. As it is not possible to diagnose early malig-
nancy by visual appearance alone, this may have led to substantial
under-reporting of oral cancer and the lack of a histological diag-
nosis makes it difficult to accurately assess the correct diagnosis
and true prevalence of these disorders. It has been argued that the
small number of randomised clusters could also produce statistical
heterogeneity and the close geographical proximity of the clusters
may have led to contamination (Kujan 2005).
Potential biases in the review process
We conducted a broad search of several databases and placed no
restrictions on the language of publication when searching the
electronic databases or reviewing reference lists of included studies.
All data extraction and risk of bias assessment was conducted in
duplicate.
Agreements and disagreements with other
studies or reviews
A meta-analysis of visual screening found a weighted and pooled
sensitivity of 84.8% (95% confidence interval (CI) 73.0 to 91.9)
and specificity of 96.5% (95% CI 93.0 to 98.2) (Downer 2004).
However, there was considerable heterogeneity in the studies
pooled due to differences in the size of the target populations and
it is arguable that a meta-analysis was inappropriate. A more re-
cent review has evaluated the diagnostic accuracy of non-special-
ist conventional oral examination, vital rinsing, light-based detec-
tion, biomarkers and mouth self examination for the identifica-
tion of individuals with suspected oral squamous cell carcinoma
or PMD. Sensitivity values for studies for all tests were varied and
relatively imprecise with sensitivity values ranging from 0.59 (0.39
to 0.78) to 0.99 (95% CI 0.97 to 1.00) for the conventional oral
examination (Walsh 2013).
These values of sensitivity and specificity for visual examination
have not been surpassed by any other type of method, such as
self examination, vital staining (toluidine blue), oral cytology or
light-based techniques (Lingen 2008; Patton 2008; Walsh 2013).
The review by Walsh et al showed sensitivity values ranging from
0.18 (95% CI 0.13 to 0.24) to 0.33 (95% CI 0.10 to 0.65) for
mouth self examination and a sensitivity value of 0.20 (95% 0.01
to 0.72) for the addition of toluidine blue (Walsh 2013). In Pat-
ton’s systematic review, 23 studies met the inclusion criteria, yet
there remained insufficient evidence to support or refute the use of
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adjunctive techniques to the visual examination (Patton 2008). In
another review, Lingen found that the majority of the published
studies had employed these techniques on patients who had al-
ready received a diagnosis and that they did not improve upon the
sensitivity or specificity of the visual examination (Lingen 2008).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results suggest that there is insufficient evidence to recom-
mend a whole population screening programme for oral cancer.
However, the results from the Kerala study suggest that a targeted
population approach could reduce the mortality rate and produce
a stage shift, but the risk of bias in the included study means that
further well-designed randomised controlled trials are necessary to
establish the validity of this relationship.
In the meantime, opportunistic visual screening by appropriately
trained dentists and oral health practitioners is recommended for
all patients and particularly for those who use tobacco, alcohol
or both. Systematic examination of the oral cavity by front-line
health workers should remain an integral part of their routine for
routine recall appointments.
Implications for research
Given the high risk of bias in the study included in this review, a
lack of randomised controlled studies associated with adjunctive
methods (e.g. brush biopsy, fluorescence imaging) and a lack of
understanding of the natural history of oral cancer, further ran-
domised controlled trials are recommended. These should ensure
the method of randomisation is accounted for in the analysis, that
there is adequate allocation concealment, a standardised interven-
tion and a clear follow-up procedure.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Sankaranarayanan 2000
Methods Randomised controlled trial, Kerala, India.
First round: 1995 to 1998.
Second round: 1998 to 2002.
Third round: 2002 to 2004.
Final assessment: 2004 to 2009.
Participants General population aged 35 years or older, all subjects 191,873 were apparently healthy
residents were grouped into intervention (n = 7 clusters, 96,517) and control (n = 6
clusters, 95,356)
Interventions Health workers interviewed the eligible subjects to extract specified information. Inter-
vention group: visual examination of the oral mucosa.
Control group: follow-up to the end point.
The intervention and control cohorts are being followed up by the Trivandrum popula-
tion-based cancer registry to determine the incidence and stage distribution of invasive
oral cancer, treatment given and mortality
Outcomes Oral cancer mortality was the major outcome. Further outcome measures were.
1. Participation: defined as “the number of eligible subjects screened as a proportion of
the total eligible in the intervention arm”.
2. Positivity rate: defined as “the proportion of screened subjects identified with referable
lesions”.
3. Detection rate: defined as “the number of subjects with lesions detected per 1000
screened subjects in the intervention group”.
4. Compliance with referral: defined as “the proportion of screen positive subjects re-
porting for diagnostic confirmation by dentists or physicians”.
5. Sensitivity, specificity, and positive predictive values.
6. Programme sensitivity and specificity: defined as “the number of screen-detected
oral cancers as a proportion of the total oral cancers in the intervention group”, “the
proportion of screen true-negative subjects among the total non-cancer-eligible subjects”
and “the number of screen-detected oral cancers as a proportion of total screen positive
subjects” respectively.
7. Incidence rate of oral cancers.
8. Characteristics of oral cancers in the study group including: the maximum dimension
of lesions, regional lymph node involvement and International Union Against Cancer/
American JointCommittee onCancer (UICC/AJCC)TNMstage groupingdistribution.
9. Case fatality for oral cancer cases diagnosed during the study period: defined as “the
number of deaths among the total number of cases”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Sankaranarayanan 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Subjects were allocated by block randomi-
sation into 13 clusters but no detail is given
about how this process was undertaken
Allocation concealment (selection bias) High risk Author of the trial stated that there was no
concealed allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding, but the review authors judge
that the outcome and its measurement are
unlikely to be influenced by this. Consid-
ered low risk
Incomplete outcome data (attrition bias)
All outcomes
High risk Not all participants attended for biopsy af-
ter screening (only 63% of screened posi-
tive compliedwith referral to have a biopsy)
. These missing data will have increased the
risk of bias
Selective reporting (reporting bias) Low risk Protocol is not available, but it appears that
the published reports include all expected
and pre-specified outcomes
Other bias Unclear risk Positive cases were referred to dentists and
physicians to make a diagnosis, but it is
unclear whether standardised criteria were
used by these clinicians or whether they
had received any training in identification
of positive lesions
It is stated that subjects with confirmed
oral cancer and PMDs were biopsied and
those with confirmed oral cancer were re-
ferred. However, although not detailed in
the first cycle, only 26.4%of subjects with a
PMD had a biopsy in the second cycle and
only 26% in the third cycle. It is not clear
whether all suspected oral cancer cases did
receive a biopsy, but given the definition of
“interval cases” in the third paper, it would
appear not. In addition, it is stated in the
third paper that the reference investigation
for final diagnosis was clinical examination
by doctors or histology or both. As it is not
possible to diagnose early malignancy by
visual appearance alone, this may have led
to substantial under-reporting of oral can-
cer. The lack of a histological diagnosis for
many of the PMDs alsomakes it difficult to
accurately assess the correct diagnosis and
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Sankaranarayanan 2000 (Continued)
true prevalence of these disorders
Prevalence of PMD and mortality data is
only provided in detail for the first two cy-
cles only. The third paper presents the re-
sults over the three cycles from 1996 to
2004 and so does not provide individual
detail about the results of the third cycle. It
is not clear why this was the case
PMDs = potentially malignant disorders.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allen 1998 Letter to author.
Chamberlain 1993 Review study.
Chen 2004 Uncontrolled clinical mass screening study.
Cheng 2003 Randomised controlled trial (diagnostic use).
Eliezri 1988 Uncontrolled study (secondary care).
Garrote 1995 Uncontrolled study.
Gray 2000 Review.
Gupta 1986 Non-randomised controlled study.
Gupta 1992 Non-randomised controlled study.
Ikeda 1991 Uncontrolled study.
Ikeda 1995 Uncontrolled study.
Lavelle 2005 Review.
Martin 1998 Uncontrolled study.
Miller 1988 Study in hamsters.
Moyer 1986 Uncontrolled study (diagnostic only).
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(Continued)
Mullhaupt 2004 Non-randomised controlled study.
Nagao 2000 Uncontrolled study.
Nagao 2000a Uncontrolled study.
Nagao 2003 Uncontrolled mass screening study.
Patton 2003 Review.
Sankaranarayanan 1997 Review study.
Sankaranarayanan 2002 Observational, case-control study.
Silverman 1984 Uncontrolled study.
Su 2010 Community-based randomised controlled trial whose primary aim was to determine whether toluidine
blue enhanced the detection rate for potentially malignant disorders
Vahidy 1972 Uncontrolled study.
Zhang 2005 Observational study.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Important potentially malignant disorders (PMDs)
The following were identified as PMDs by theWorld Health Organization’s Working Group on Oral Cancer (Warnakulasuriya 2007)
.
• Leukoplakia.
• Erythroplakia.
• Palatal lesion of reverse cigar smoking.
• Oral lichen planus.
• Oral submucous fibrosis.
• Discoid lupus erythematosus.
• Hereditary disorders such as dyskeratosis congenita and epidermolysis bullosa.
Table 2. Comparison of risk factors between the intervention and control groups after three cycles (nine years) follow-up
Trivandrum Oral Cancer Screening
Study
Screening group Control group
Number of interviewed participants n = 7 clusters (87,829: 91%) n = 6 clusters (80,086: 84%)
Gender 35,687 male
52,142 female
31,281 male
48,805 female
Income (< 1500 rupees (USD 35) per
month)
42,415 (49%) 30,849 (40%)
Occupation (manual workers) 68,645 (78%) 55,811 (71%)
Education 68,263 (78%) 64,291 (78%)
Age (years; mean (SD, range)) 49 (0.7, 48-50) 49 (0.8, 48-50)
No habits 10,933 male (27%)
39,923 female (73%)
13,996 male (33%)
42,361 female (79%)
Chewing habits 12,329 male (30%)
14,570 female (27%)
10,586 male (24.9%)
10,748 female (20%)
Smoking habits 26,133 male (63%)
1610 female (3%)
23,270 male (56%)
609 female (1%)
Drinking habits 17,738 male (43%)
133 female (0.2%)
15,472 male (37%)
127 female (0.1%)
SD = standard deviation.
22Screening programmes for the early detection and prevention of oral cancer (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Note: Data on risk factors not available after 4 cycles (15 years), but authors report that the participants had a similar distribution.
Table 3. Screening history after four cycles (15 years) follow-up
Screening history Screening group Control
Number recruited 7 clusters
(n = 96,517)
6 clusters
(n = 95,356)
Not screened 7695 51,365
Screened once 25,144 43,992
Screened twice 22,382
Screened three times 22,008
Screened four times 19,288
Number of screen positive individuals 5586 1163
Individuals complied with referral 3298 189
Table 4. Oral cancer experience after four cycles (15 years) follow-up
Trivandrum Oral Cancer
Screening Study
Screening group Control group Risk ratio (95% confidence interval)
Total number participants 96,517 95,356
Person-years of observation 895,310 898,280
Number of oral cancers 279 244
Screen detected cases 188 Nil
Deaths from oral cancer 138 154
Case fatality rate 49.5% 63.1%
Crude incidence rate / 100,000
person-years of observation
31.2 27.2 1.14 (0.91 to 1.44)
Age-standardised incidence rate
/ 100,000 person-years
37.1 30.8
Crude mortality rate from oral
cancer /100,000 person-years
of observation
15.4 17.1 0.88 (0.69 to 1.12)
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Table 4. Oral cancer experience after four cycles (15 years) follow-up (Continued)
Age-standardised mortality rate
/ 100,000 person-years
18.9 19.7
Proportion of cancers at stage
III or worse1
52.6% 65.2% 0.81 (0.70 to 0.93)
1Does not include individuals for whom stage unknown (22 in screening group; 19 in control group).
Table 5. Oral cancer experience in high-risk individuals after four cycles (15 years) follow-up
Trivandrum Oral Cancer
Screening Study
Screening group Control group Risk ratio (95% confidence interval)
Person-years of observation 429,620 377,350
Number of oral cancer cases 254 232
Deaths from oral cancer 129 147
Case fatality rate 50.8% 63.4%
Crude incidence rate/ 100,000
person-years
59.2 61.6 0.97 (0.79 to 1.19)
Age-standardised incidence
rate/ 100,000 person-years
57.3 58.5
Crude mortality rate/ 100,000
person-years
30.0 39.0 0.76 (0.60 to 0.97)
Age-standardised mortality
rate/ 100,000 person-years
29.1 37.1
Age-standardised mortality
rate/ 100,000 person-years
18.9 19.7
Proportion of cancers at stage
III or worse1
54.3% 66.4% 0.82 (0.71 to 0.95)
1Does not include individuals for whom stage unknown (22 in screening group; 19 in control group).
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Table 6. Oral cancer mortality rate by number of times screened
Risk type Arm Cycles Mortality rate* Hazard ratio (95% confidence interval)**
All participants Control n/a 17.1 1.00
Screening group 0 37.2 1.46 (0.78 to 2.73)
1 44.1 2.26 (1.66 to 3.09)
2 16.2 0.94 (0.68 to 1.30)
3 10.4 0.62 (0.37 to 1.04)
4 3.0 0.21 (0.13 to 0.35)
High-risk participants Control n/a 39.0 1.00
Screening group 0 59.4 1.27 (0.68 to 2.37)
1 74.7 1.90 (1.45 to 2.49)
2 31.0 0.83 (0.62 to 1.12)
3 20.6 0.53 (0.34 to 0.84)
4 7.1 0.19 (0.11 to 0.31)
*Per 100,000 person-years of observation
**Adjusted for age, sex and number of residents.
Table 7. Distribution of stage over four cycles (15 years)
Arm Cycles Clinical stage Total
I II III IV Unknown
Intervention
group
Baseline 0 3 (16%) 3 (16%) 7 (37%) 6 (32%) 19
1 9 (11%) 10 (13%) 18 (23%) 32 (41%) 10 (13%) 79
2 10 (15%) 11 (17%) 17 (26%) 25 (38%) 3 (5%) 66
3 23 (32%) 12 (17%) 9 (13%) 25 (35%) 3 (4%) 72
4 17 (40%) 15 (35%) 4 (9%) 7 (34%) 0 43
Total 59 (21%) 51 (18%) 51 (18%) 96 (34%) 22 (8%) 279
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Table 7. Distribution of stage over four cycles (15 years) (Continued)
Control
group
1996 - 2004
(detected not
due to screen-
ing)
21 (13%) 19 (12%) 34 (22%) 72 (46%) 12 (8%) 158
Not screened 0 7 (16%) 12 (27%) 20 (44%) 6 (13%) 45
Screened 10 (24%) 9 (22%) 6 (15%) 15 (37%) 1 (2%) 41
Total 31 (13%) 35 (14%) 52 (21%) 107 (44%) 19 (8%) 244
Table 8. Cost-effectiveness of the screening programme after three cycles (nine years)
Detail Cost of intervention less cost of control (US$)
Total cost per 100,000 individuals 224,964
Cost per additional cancer detected by the
screen
All individuals 4817
Cost per additional cancer detected by the
screen
High-risk individuals 9394
Cost per life-year saved by the screen All individuals 835
Cost per life-year saved by the screen High-risk individuals 156
Costs based on the calender year of 2004 (Subramanian 2009).
A P P E N D I C E S
Appendix 1. MEDLINE via OVID search strategy
1. exp MOUTH/
2. exp LIP/
3. exp GINGIVA/
4. exp TONGUE/
5. exp OROPHARYNX/
6. exp HYPOPHARYNX/
7. exp PALATE/
8. exp CHEEK/
9. (mouth or lip$ or tongue$ or gingiv$ or oropharynx or palate or cheek$).mp. [mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
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10. or/1-9
11. exp MOUTH NEOPLASMS/
12. exp PRECANCEROUS CONDITIONS/
13. (tumor$ or tumour$ or cancer$ or carcinoma$).mp. [mp=title, original title, abstract, name of substance word, subject heading
word, unique identifier]
14. malignan$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
15. dysplasia$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
16. (oral adj6 cancer$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
17. or/11-16
18. MASS SCREENING/
19. (visual$ adj screen$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
20. tolonium chloride.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
21. TOLONIUM CHLORIDE/
22. “toluidine blue”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
23. exp TOLUIDINES/
24. “toluidine dye”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
25. (“brush biopsy” or “exfoliate cytology”).mp. [mp=title, original title, abstract, name of substance word, subject heading word,
unique identifier]
26. “fluorescent imaging”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
27. (“fluorescent dye$” or “fluorescent antibody technique” or fluorescence).mp. [mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
28. prevent$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
29. screen$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
30. (early adj3 detect$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
31. or/18-30
32. 10 and 17 and 31
The above subject search was linked to the the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in
MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of theCochrane
Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
Appendix 2. Cochrane Oral Health Group’s Trials Register search strategy
From 2013, searches of the Cochrane Oral Health Group’s Trials Register were updated using the Cochrane Register of Studies software
and the search strategy below:
#1 (tumor* or tumour* or cancer* or carcinoma* or malignan*):ti,ab
#2 (screen* or tolonium or “brush biopsy” or “exfoliative cytology” or fluorescen* or “early detect*”):ti,ab
#3 #1 and #2
Previous searches of the Oral Health Group’s Trials Register were undertaken using the Procite software and the search strategy below:
((tumor* or tumour* or cancer* or carcinoma* or malignan*) AND (screen* or tolonium or “brush biopsy” or “exfoliative cytology”
or fluorescen* or “early detect*”))
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Appendix 3. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
#1 MeSH descriptor MOUTH explode all trees
#2 MeSH descriptor LIP explode all trees
#3 MeSH descriptor GINGIVA this term only
#4 MeSH descriptor TONGUE explode all trees
#5 MeSH descriptor OROPHARYNX explode all trees
#6 MeSH descriptor HYPOPHARYNX explode all trees
#7 MeSH descriptor PALATE explode all trees
#8 MeSH descriptor CHEEK this term only
#9 (mouth* in All Text or lip* in All Text or tongue* in All Text or gingiv* in All Text or oropharnyx in All Text or palate* in All Text
or cheek* in All Text)
#10 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)
#11 MeSH descriptor MOUTH NEOPLASMS explode all trees
#12 MeSH descriptor PRECANCEROUS CONDITIONS explode all trees
#13 (tumor* in All Text or tumour* in All Text or cancer* in All Text or carcinoma* in All Text)
#14 malignan* in All Text
#15 dysplasia* in All Text
#16 (oral in All Text near/6 cancer* in All Text)
#17 (#11 or #12 or #13 or #14 or #15 or #16)
#18 MeSH descriptor Mass Screening explode all trees
#19 “visual* screen*” in All Text
#20 “tolonium chloride” in All Text
#21 MeSH descriptor TOLONIUM CHLORIDE this term only
#22 “toluidine blue” in All Text
#23 MeSH descriptor TOLUIDINES explode all trees
#24 “toluidine dye” in All Text
#25 (“brush biopsy” in All Text or “exfoliate cytology” in All Text)
#26 “fluorescent imaging” in All Text
#27 (“fluorescent dye*” in All Text or “fluorescent antibody technique” in All Text or fluorescence in All Text)
#28 prevent* in All Text
#29 screen* in All Text
#30 (early in All Text near/3 detect* in All Text)
#31 (#18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30)
#32 (#10 and #17 and #31)
Appendix 4. EMBASE via OVID search strategy
1. exp MOUTH/
2. exp LIP/
3. exp GINGIVA/
4. exp TONGUE/
5. exp OROPHARYNX/
6. exp HYPOPHARYNX/
7. exp PALATE/
8. exp CHEEK/
9. (mouth or lip$ or tongue$ or gingiv$ or oropharynx or palate or cheek$).mp. [mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
10. or/1-9
11. exp MOUTH NEOPLASMS/
12. exp PRECANCEROUS CONDITIONS/
13. (tumor$ or tumour$ or cancer$ or carcinoma$).mp. [mp=title, original title, abstract, name of substance word, subject heading
word, unique identifier]
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14. malignan$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
15. dysplasia$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
16. (oral adj6 cancer$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
17. or/11-16
18. MASS SCREENING/
19. (visual$ adj screen$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
20. tolonium chloride.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
21. TOLONIUM CHLORIDE/
22. “toluidine blue”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
23. exp TOLUIDINES/
24. “toluidine dye”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
25. (“brush biopsy” or “exfoliate cytology”).mp. [mp=title, original title, abstract, name of substance word, subject heading word,
unique identifier]
26. “fluorescent imaging”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
27. (“fluorescent dye$” or “fluorescent antibody technique” or fluorescence).mp. [mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
28. prevent$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
29. screen$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
30. (early adj3 detect$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
31. or/18-30
32. 10 and 17 and 31
The above subject search was linked to the Cochrane Oral Health Group filter for identifying RCTs in EMBASE via OVID.
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
8. allocat$.ti,ab.
9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
16. 14 NOT 15
Appendix 5. CANCERLIT via PubMed search strategy
#1 Search MOUTH [mh:exp]
#2 Search LIP [mh:exp]
#3 Search GINGIVA [mh:exp]
#4 Search TONGUE [mh:exp]
#5 Search OROPHARYNX [mh:exp]
#6 Search HYPOPHARYNX [mh:exp]
#7 Search PALATE [mh:exp]
#8 Search CHEEK [mh:exp]
#9 Search (mouth or lip* or tongue* or gingiv* or oropharynx or palate or cheek*)
#10 Search #1 or #2 or #3 pr #4 or #5 or #6 or #7 or #8 or #9
#11 Search MOUTH NEOPLASMS [mh:exp]
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#12 Search PRECANCEROUS CONDITIONS [mh:exp]
#13 Search (tumor* or tumour* or cancer* or carcinoma*)
#14 Search malignan*
#15 Search dysplasia*
#16 Search “oral cancer*”
#17 Search #11 or #12 or #13 or #14 or #15 or #16
#18 Search MASS SCREENING [mh:exp]
#19 Search “visual* screen*”
#20 Search “tolonium chloride”
#21 Search TOLONIUM CHLORIDE [mh:noexp]
#22 Search “toluidine blue”
#23 Search TOLUIDINES [mh:exp]
#24 Search “toluidine dye”
#25 Search (“brush biopsy” or “exfoliate cytology”)
#26 Search “fluorescent imaging”
#27 Search (“fluorescent dye*” or “fluorescent antibody technique” or fluorescence)
#28 Search prevent*
#29 Search screen*
#30 Search “early detect*”
#31 Search #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30
The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in
MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.a of the Cochrane
Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).
#1 randomized controlled trial [pt]
#2 controlled clinical trial [pt]
#3 randomized [tiab]
#4 placebo [tiab]
#5 drug therapy [sh]
#6 randomly [tiab]
#7 trial [tiab]
#8 groups [tiab]
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10 animals [mh] NOT humans [mh]
#11 #9 NOT #10
WH A T ’ S N E W
Last assessed as up-to-date: 22 July 2013.
Date Event Description
12 September 2013 New search has been performed Searches updated on 22 July 2013.
12 September 2013 New citation required but conclusions have not
changed
This version includes a change in authors. Review text,
methodology, background and references brought up
to date
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H I S T O R Y
Protocol first published: Issue 2, 2003
Review first published: Issue 4, 2003
Date Event Description
6 October 2010 New citation required but conclusions have not changed New authorship.
6 October 2010 New search has been performed New searches and methodology. Review text, back-
ground and references brought up to date
25 May 2006 New citation required but conclusions have not changed This version includes a change in authors.
23 May 2006 New search has been performed The current review reflects the results of anupdate search
conducted in July 2005. No new trials were identified as
meeting the review’s inclusion criteria. However, a trial
presenting the final analysis for the one, previously in-
cluded trial was identified. The conclusions of the re-
view remain the same
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